Molybdenum cofactor deficiency in the neonate – expanding the phenotype

Fátima Hierro,Maria Tomé,Joana Grenha,Helena Santos,Fátima Santos,Joana Nunes

DOI: https://doi.org/10.1016/j.pediatrneurol.2024.01.020

IF: 4.21

2024-02-03

Pediatric Neurology

Abstract:Molybdenum cofactor deficiency (MoCoD) is a rare metabolic disorder that affects the biosynthesis of the molybdenum cofactor, an essential cofactor for several enzymes including sulfite oxidase which leads to a buildup of toxic levels of sulfite. It can cause various neurological symptoms usually severe from the neonatal period, including intractable seizures and developmental delay [1][2]. Neuroradiological imaging can aid in the diagnosis. Early findings are often severe, including diffuse edema which rapidly becomes similar to the presentation of severe hypoxic ischemic injury [3],[4]. Within a few weeks, there is white matter loss and cortical atrophy with cyst formation [5],[6],[3]. A pattern of diffuse white matter restricted diffusion sparing the cortex, with subsequent progression to multi-cystic leukomalacia, has also been described in MoCoD [7]. There are few published cases of hemorrhagic lesions in individuals with MoCoD [8]. The exact mechanism by which MoCoD leads to hemorrhagic lesions is not well understood. Treatment involves the administration of a precursor compound called cyclic pyranopterin monophosphate, which can restore the activity of sulfite oxidase. It is solely applicable for type A MoCoD, preventing the progression of neurodegeneration when started pre-symptomatically [9]. However, the neurological symptoms are severe and require ongoing management and support [10].

pediatrics,clinical neurology